Search results

Create the page "Pediatric shake" on this wiki! See also the search results found.

Abametapir
* Use is not recommended in pediatric patients under 6 months of age because of the potential for increased syste * Shake well before use.

4 KB (591 words) - 14:00, 5 July 2021
Ansuvimab-zykl
...for the treatment of infection caused by [[Zaire ebolavirus]] in adult and pediatric patients, including neonates born to a mother who is [[RT-PCR]] positive fo *The recommended dose of EBANGA for adult and pediatric patients is '''50 mg/kg''' reconstituted, further diluted, and administered

4 KB (629 words) - 17:07, 25 June 2021
Asparaginase erwinia chrysanthemi
...blastic leukemia]] (ALL) and [[lymphoblastic lymphoma]] (LBL) in adult and pediatric patients 1 month or older who have developed [[hypersensitivity]] to [[E. c * Do not shake the vial.

6 KB (854 words) - 13:52, 8 June 2022
Calaspargase pegol
...c enzyme''' used for the treatment of [[acute lymphoblastic leukemia]] in pediatric and young adult. ...apeutic]] regimen for the treatment of [[acute lymphoblastic leukemia]] in pediatric and young adult patients age 1 month to 21 years.

7 KB (921 words) - 13:59, 8 June 2022
Dinutuximab
...d [[13-cis retinoic acid|13-cis-retinoic acid]] (RA), for the treatment of pediatric patients with high-risk [[neuroblastoma]] who achieve at least a partial re ...46°F). Protect from light by storing in the outer carton. DO NOT FREEZE OR SHAKE vials.

7 KB (958 words) - 08:00, 27 June 2022
Elosulfase alfa
* Do not shake the solution. * Safety and effectiveness of Vimizim have been established in pediatric patients 5 years of age and older.

6 KB (960 words) - 15:08, 4 September 2021
Burosumab
* The treatment of [[X-linked hypophosphatemia]] (XLH) in adult and pediatric patients 6 months of age and older. ...ymal tumors]] that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.

8 KB (1,186 words) - 15:33, 6 July 2023
Sacubitril and valsartan
...matic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. It reduces NT-proBNP and is expected to i ...approved by US FDA on Jul 7, 2015 for heart failure and on Oct 1, 2019 for pediatric heart failure.

6 KB (893 words) - 18:14, 23 July 2021
Erenumab-aooe
* Do not shake the product. * Safety and effectiveness in pediatric patients have not been established.

6 KB (805 words) - 16:54, 8 August 2023
Erenumab
* Do not shake the product. * Safety and effectiveness in pediatric patients have not been established.

6 KB (847 words) - 16:52, 8 August 2023
Cefuroxime
* [[Pharyngitis]]/[[tonsillitis]] (adults and pediatric patients) * Acute bacterial [[otitis media]] (pediatric patients)

11 KB (1,424 words) - 04:31, 6 March 2024
Remimazolam
* Gently swirl the vial (do not shake) until the contents are fully dissolved. * since this medicine may cause pediatric Neurotoxicity.

6 KB (773 words) - 17:06, 5 July 2021
Barium sulfate suspension
...ze the [[Gastrointestinal tract|gastrointestinal (GI) tract]] in adult and pediatric patients. * '''Pediatric Patients:''' Adjust dose based on GI volume

9 KB (1,359 words) - 16:55, 1 November 2022
Sebelipase alfa
'''Pediatric and Adult Patients with LAL Deficiency:''' '''Pediatric and Adult Patients'''

7 KB (976 words) - 12:49, 1 September 2021
Glucarpidase
...otrexate]] concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentra * Roll and tilt the vial gently to mix. Do not shake.

6 KB (838 words) - 15:44, 3 September 2022
Vestronidase alfa-vjbk
This medicine is used in pediatric and adult patients for the treatment of [[Mucopolysaccharidosis]] VII (MPS * The safety and effectiveness of MEPSEVII have been established in pediatric patients less than 18 years of age.

5 KB (777 words) - 17:04, 8 August 2021
Olaratumab
* Gently invert but do not shake. * The safety and effectiveness of LARTRUVO in pediatric patients have not been established.

6 KB (820 words) - 14:24, 19 August 2021
Azelastine hydrochloride and fluticasone propionate
* Shake the bottle gently before each use. ...y when administered to pediatric patients. Monitor the growth routinely of pediatric patients receiving DYMISTA.

8 KB (1,161 words) - 13:33, 12 January 2022
Atoltivimab/maftivimab/odesivimab
...for the treatment of infection caused by [[Zaire ebolavirus]] in adult and pediatric patients, including neonates born to a mother who is [[RT-PCR]] positive fo ...atment of infection caused by Zaire ebolavirus '''have been established in pediatric patients from birth to less than 18 years of age'''.

6 KB (840 words) - 15:21, 3 July 2023
Atoltivimab, maftivimab, and odesivimab-ebgn
...for the treatment of infection caused by [[Zaire ebolavirus]] in adult and pediatric patients, including neonates born to a mother who is [[RT-PCR]] positive fo ...atment of infection caused by Zaire ebolavirus '''have been established in pediatric patients from birth to less than 18 years of age'''.

6 KB (841 words) - 15:19, 3 July 2023